NitroMed to Present at JPMorgan Healthcare Conference.- January 11 at 9:30 am PT - LEXINGTON, Mass. -- First graph and subhead sub·head n. In both senses also called subheading. 1. The heading or title of a subdivision of a printed subject. 2. A subordinate heading or title. Noun 1. of release, presentation time should read: 9:30 am PT (sted 8:30 am PT). The corrected release reads: NITROMED TO PRESENT AT JPMORGAN HEALTHCARE CONFERENCE January 11 at 9:30 am PT NitroMed Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NTMD) today announced that Kenneth M. Bate bate 1 tr.v. bat·ed, bat·ing, bates 1. To lessen the force or intensity of; moderate: "To his dying day he bated his breath a little when he told the story" , the Company's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. and Chief Financial Officer, will present at the 25th Annual JPMorgan Healthcare Conference, being held in San Francisco from January 7 - 11 at the Westin St. Francis hotel The Westin St. Francis is a luxury hotel in the Union Square district of San Francisco, California. The hotel opened on March 21, 1904. The interior was destroyed in the 1906 Earthquake but the structure survived and the hotel re-opened in late 1907. . Mr. Bate will update investors on the Company's progress during its presentation on Thursday, January 11 at 9:30 am (PT). The 30-minute NitroMed update will be webcast and may be accessed by visiting the Investor Relations section of the Company's website (www.nitromed.com). This event will be archived on the NitroMed website for a limited period of time following the conference. About NitroMed, Inc. NitroMed of Lexington, Massachusetts is an emerging pharmaceutical company and the maker of BiDil([R]) (isosorbide dinitrate/hydralazine hydrochloride), an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as angiotensin converting enzyme Noun 1. angiotensin converting enzyme - proteolytic enzyme that converts angiotensin I into angiotensin II angiotensin-converting enzyme, ACE peptidase, protease, proteinase, proteolytic enzyme - any enzyme that catalyzes the splitting of proteins into (ACE) inhibitors and beta blockers. There is little experience in patients with New York Heart Association Class IV heart failure. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial and is marketed by NitroMed through a specialty medicines sales organization. For full prescribing information, visit: www.BiDil.com. BiDil is a registered trademark of NitroMed, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion